Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679592 | 0.77 | SIGMAR1 (0.35) | SIGMAR1HTR6SLC6A4SLC6A3KCNH2 | |
| SCHEMBL684859 | 0.75 | SIGMAR1 (0.35) | SIGMAR1HTR6MCHR1 | |
| SCHEMBL679784 | 0.70 | CCNA2 (0.37) | SLC6A4SLC6A3KCNH2MCHR1 | |
| SCHEMBL15028241 | 0.62 | SLC6A4 (0.37) | SIGMAR1HTR6SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7967958 | 0.58 | — | — | |
| SCHEMBL25450535 | 0.56 | SIGMAR1 (0.38) | SIGMAR1SLC6A4SLC6A3KCNH2 | |
| SCHEMBL25464888 | 0.56 | SIGMAR1 (0.38) | SIGMAR1SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7809777 | 0.55 | CYP3A4 (0.36) | SIGMAR1KCNH2 | |
| SCHEMBL7808288 | 0.55 | HSD11B1 (0.45) | SIGMAR1HTR6SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7704785 | 0.54 | CHRM2 (0.36) | SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | SIGMAR1 3434/4885HTR6 2188/4885SLC6A4 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.